People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Castle Creek Biosciences, Inc. | — | Biotechnology | Growth/Late | $839.8M | $804.8M | 2019 |
| Paragon Biosciences Emalex Capital, Inc. | — | Pharmaceuticals | Series D+ | $376.8M | $5.5B | 2022 |
| Tesla, Inc. | — | Other Technology | Series D+ | $246.6M | $632.7M | 2009 |
| Evozyne, Inc. | — | Biotechnology | Series C | $144.4M | $979.0M | 2020 |
| Solarcity Corp | — | Other Technology | Series C | $80.8M | $2.1B | 2012 |
| CIRC Biosciences, Inc. | — | Biotechnology | Series B | $24.1M | $54.7M | 2020 |
| Paragon Biosciences Qlarity Capital, Inc. | — | Pharmaceuticals | Series B | $15.0M | $510.1M | 2019 |
Antonio J. Gracias at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Antonio J. Gracias on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick J. Morris | 5 | 8 |
| Antonio Gracias | 4 | 15 |
| Darien J. Parhad | 4 | 7 |
| Jeffrey S. Aronin | 4 | 4 |
| Patrick Morris | 3 | 6 |
| Jeffrey Aronin | 3 | 6 |
| Timothy Cunniff | 3 | 5 |
| Darien Parhad | 3 | 4 |
| Elon Musk | 2 | 6 |
| Jeffrey B Straubel | 2 | 3 |
| Timothy M. Cunniff | 2 | 2 |
| David White | 1 | 11 |
| Steve Jurvetson | 1 | 10 |
| Ira Ehrenpreis | 1 | 10 |
| Steve Westly | 1 | 7 |
| Kimbal Musk | 1 | 5 |
| Michael Derby | 1 | 5 |
| John H.N. Fisher | 1 | 3 |
| Steve J Jurvetson | 1 | 3 |
| Brad Buss | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.